Pillar Biosciences Announces Online Publication of Data in the Journal of Clinical Oncology

Pillar Biosciences Announces Online Publication of Data in the Journal of Clinical Oncology

May 31, 2022 by Business Wire Health: Oncology News

Key Facts

  • NATICK, Mass.--(BUSINESS WIRE)--Pillar Biosciences, the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) tests to localize testing and reduce time to treatment initiation and overall testing costs, today announced that its abstract, “Reducing Pre-analytical Sample QC Failure Rates for Cancer Molecular Genetic Assays with SLIMamp® Technology”, has been published online in the Journal of Clinical Oncology, in conjunction with the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting.
  • “The findings from our study underscore the accuracy and reliability of our SLIMamp® technology and demonstrate its ability to generate highly accurate results from lower quality samples that have failed other NGS tests.
  • The study showed that oncoReveal™ Solid Tumor Panel with Pillar Biosciences’ proprietary SLIMamp® technology, was able to generate reliable, interpretable results for almost all of the samples that had failed pre-analytical QC for WES.
  • About Pillar Biosciences Pillar Biosciences is the leader in Decision Medicine™, which is the utilization of highly accurate and sensitive next-generation sequencing (NGS) testing technology to generate data that optimizes selection of precision therapies for cancer patients, from tumor profiling to therapy selection, and recurrence monitoring.

Click To Read Full Article

ORGANIZATION
EVENT
PERCENT
CRYPTOCURRENCY
WORK OF ART
PRODUCT
GEOGRAPHY
PERSON
MISCELLANEOUS

This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.

Was this content valuable for you?